Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma

Purpose: CD8+ CTLs have an essential role in immune response against tumor. Although tumor-associated antigens have been identified in renal cell carcinoma (RCC), few of these are commonly shared and investigated as therapeutic targets in the clinical medicine. In this report, we show that HIFPH3, a member of prolyl hydroxylases that function as oxygen sensor, is a novel tumor antigen and HIFPH3-specific CTLs are induced from peripheral blood lymphocytes of RCC patients. Experimental Design: Expression of HIFPH3 was examined by reverse transcription-PCR and immunostaining with anti-HIFPH3 antibody. To identify HLA-A24-restricted T-cell epitopes of HIFPH3, eight peptides were selected from the amino acid sequence of this protein and screened for their binding affinity to HLA-A24. Peptide-specific CTLs were induced by stimulating peripheral blood lymphocytes of HLA-A24-positive RCC patients with these peptides in vitro. HLA-A24-restricted cytotoxicity of the CTLs against HIFPH3+ RCC lines was assessed by chromium release assay. Results: HIFPH3 was overexpressed in many RCC cell lines and primary RCC tissues, whereas it was not detectable in normal adult tissues by reverse transcription-PCR. Of the eight peptides that contained HLA-A24-binding motif, HIFPH3-8 peptide (amino acid sequence, RYAMTVWYF) could induce the peptide-specific CTLs from 3 of 6 patients with HIFPH3-positive RCC. Furthermore, HIFPH3-8 peptide-specific CTLs showed cytotoxicity against HIFPH3+ RCC cell lines in a HLA-A24-restricted manner. Conclusions: HIFPH3 may be a target antigen in immunotherapy for RCC and HIFPH3-8 peptide could be used as a peptide vaccine for HLA-A*2402+/HIFPH3+ RCC patients.

[1]  J Philip McCoy,et al.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.

[2]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[3]  D. Bowtell,et al.  Siah2 Regulates Stability of Prolyl-Hydroxylases, Controls HIF1α Abundance, and Modulates Physiological Responses to Hypoxia , 2004, Cell.

[4]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[5]  J. Pouysségur,et al.  HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.

[6]  B. Bowen,et al.  Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. , 2003, Biochemical and biophysical research communications.

[7]  Jianhe Huang,et al.  Sequence Determinants in Hypoxia-inducible Factor-1α for Hydroxylation by the Prolyl Hydroxylases PHD1, PHD2, and PHD3* , 2002, The Journal of Biological Chemistry.

[8]  V. Rotter,et al.  Falkor, a novel cell growth regulator isolated by a functional genetic screen , 2002, Oncogene.

[9]  Mircea Ivan,et al.  Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Yamashita,et al.  Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma1 , 2002, The Journal of Immunology.

[11]  K. Kamiguchi,et al.  An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  R. Figlin,et al.  Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. , 2001, The New England journal of medicine.

[13]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[14]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[15]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[16]  T. Tsurumi,et al.  Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. , 2001, Blood.

[17]  K. Hirata,et al.  Detection of anti-livin antibody in gastrointestinal cancer patients. , 2001, Clinical chemistry.

[18]  S. White,et al.  HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Yang,et al.  Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.

[20]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[21]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[22]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[23]  Y. Nishimura,et al.  Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer‐associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome , 2001, European journal of immunology.

[24]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[25]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[26]  J. Mosnier,et al.  Flow cytometric analysis of antigen expression in malignant and normal renal cells. , 2000, Anticancer research.

[27]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[28]  B. Seliger,et al.  Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? , 1998, Cancer research.

[29]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[30]  A. Rickinson,et al.  Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.

[31]  M F del Guercio,et al.  Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.

[32]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[34]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[35]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[36]  N. Sato,et al.  Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. , 1986, Cancer research.